Akademik Veri Yönetim Sistemi
Uludağ Üniversitesi Tıp Fakültesi Dergisi, cilt.51, sa.3, ss.379-386, 2025 (TRDizin)
Chronic urticaria (CU) is a condition characterized by recurrent pruritic wheals that significantly impair quality of life. This study aimed to evaluate the prevalence of anxiety, depression, sleep disorders, and fibromyalgia syndrome (FMS) in CU patients and to compare these outcomes with controls. The study included 161 CU patients and 155 controls with dermatological conditions other than CU. Comprehensive clinical, sociodemographic, and laboratory data were collected, including metabolic syndrome parameters, psychiatric assessments, and sleep quality measures. 68.3% of the CU patients were female. Compared with males, female patients had later disease onset (p=0.002), lower educational levels (p=0.025), and a higher prevalence of thyroid disease (p=0.024), elevated thyroid autoantibodies (p=0.032), and FMS (p=0.028). Compared to controls, CU patients had significantly higher rates of FMS (p<0.001), moderate to severe depression (p<0.001), increased visual analogue scale (VAS) pain scores (p<0.001), greater antidepressant use (p<0.001), and poorer sleep quality (p<0.001). Uncontrolled CU, determined by Urticaria Activity Score (UAS7), was associated with higher VAS pain scores (p<0.001), increased FMS prevalence (p<0.001), greater depression rates (p=0.008), and more frequent sleep disturbances (p=0.009). Additionally, the Hospital Anxiety and Depression Scale (HADS)-anxiety scores were significantly lower in omalizumab users (p=0.028), indicating an observed association that may reflect improved disease management rather than a direct treatment effect. Our findings highlight the significant physical and psychological burden of CU, especially in women and patients with uncontrolled disease, and emphasize the importance of considering comorbid conditions such as fibromyalgia, depression and sleep disorders.